Scientists are rapidly focused on retatrutide, a promising medication created by Eli Lilly, as a significant advance in body loss . Different than many previous approaches, retatrutide is a double -action agonist targeting equally GLP-1 and GIP, chemicals that impact satiety and blood glucose contr